A2B395 Produces Early Logic-Gated CAR-T Responses

Company A2 Biotherapeutics Event Type Early Clinical Data (DENALI-1) Modality Allogeneic Logic-Gated CAR-T (Tmod) Asset A2B395 Target EGFR (Activator) / HLA-A*02 (Blocker) Disease Area Solid Tumors (Anal, Head-and-Neck, Lung, Colorectal, Breast Cancer) Summary Early DENALI-1 data from ten adults treated with the allogeneic, EGFR-directed A2B395…